MS4A1 and renal cell adenocarcinoma: One notable implication of the observation that CD20+ B-lymphocytes is associated with worse survival of RCC patients, is that different CD20-directed therapies, presently approved for B-cell lymphomas32 can be considered as a treatment regimen for this novel subset of RCC.